SCHEMBL2113619

SCHEMBL2113619

c1ccc(Cc2cc3cccnc3[nH]2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.53
DRD4 P21917 2/20 0.53
DRD3 P35462 2/20 0.53
DAO P14920 1/20 0.49
CCNK O75909 1/20 0.48
CDK12 Q9NYV4 1/20 0.48
ADORA1 P30542 1/20 0.47
RIPK1 Q13546 5/20 0.47
MET P08581 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
AOC3 Q16853 1/20 0.44
KDM4A O75164 1/20 0.43
KDM5A P29375 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
MAPK14 Q16539 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20005178 0.86 PRMT5 (0.47) DRD2DRD4DRD3DAORIPK1
SCHEMBL3492565 0.85 DRD2 (0.58) DRD2DRD4DRD3DAORIPK1
SCHEMBL1362779 0.80 RIPK1 (0.55) DRD2DRD4DRD3DAORIPK1
SCHEMBL2176426 0.77 LOXL2 (0.52) DRD2DRD4DRD3DAORIPK1
SCHEMBL1939638 0.77 DRD2 (0.50) DRD2DRD4DRD3DAORIPK1
SCHEMBL25230913 0.77 DRD2 (0.50) DRD2DRD4DRD3DAORIPK1
SCHEMBL13543890 0.77 RIPK1 (0.58) DRD2DRD4DRD3DAOCCNK
SCHEMBL17451039 0.77 DRD2 (0.50) DRD2DRD4DRD3DAORIPK1
SCHEMBL28168400 0.76 AOC3 (0.47) CCNKCDK12ADORA1CDK2AOC3
SCHEMBL28168225 0.76 AOC3 (0.44) CCNKCDK12ADORA1AOC3KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4440573-A1 NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME Mydecine Innovations Group Inc. (US) 2024-10-09 EP disclosed
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-04-09 US disclosed
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2024-03-28 US disclosed
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-03-26 US disclosed
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2023-11-02 US disclosed
EP-4255422-A1 NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME Mydecine Innovations Group Inc. (US) 2023-10-11 EP disclosed
US-20230271924-A1 Novel Psilocin Analog Compositions And Methods of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2023-08-31 US disclosed
WO-2023101722-A1 NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME MEDECINE INNOVATIONS GROUP INC. (US) 2023-06-08 WO disclosed
WO-2022120181-A1 NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME MYDECINE INNOVATIONS GROUP INC. (US) 2022-06-09 WO disclosed
US-8158647-B2 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
EP-2056822-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-05-13 EP disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed
WO-2008150914-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-12-11 WO disclosed
US-20060183758-A1 Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans CB RESEARCH AND DEVELOPMENT, INC. (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 DRD2 425/4885DRD4 249/4885DRD3 861/4885
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 DRD2 425/4885DRD4 249/4885DRD3 861/4885
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 DRD2 584/4885DRD4 363/4885DRD3 1174/4885
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS PDXK, MAP3K4, PDPK1 DRD2 2958/4885DRD4 3643/4885DRD3 3442/4885
US-20230271924-A1 Novel Psilocin Analog Compositions And Methods of Synthesizing The Same PSAP, ABCG2, PSAT1 DRD2 357/4885DRD4 374/4885DRD3 581/4885
US-20060183758-A1 Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans TPMT, INMT, AANAT DRD2 1089/4885DRD4 262/4885DRD3 895/4885
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 DRD2 584/4885DRD4 363/4885DRD3 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.